Sidley represented San Francisco, California-based Tricida, Inc. in its $222 million initial public offering (IPO) of common stock. Tricida is a pharmaceutical company focused on the development and commercialization of its lead product candidate, TRC101, a non-absorbed, orally administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. The stock was listed on NASDAQ under the symbol “TCDA.” The IPO was the second largest biotechnology IPO since January 1, 2016.*
The multi-office Sidley IPO team was led by Geoffrey Levin and Istvan Hajdu and included Tricia Hojo, Sharon Flanagan, Kevin Blatchford, Michael Hyatte and Patricia Wood provided capital markets support. Corey Perry provided executive compensation advice with help from P.C. Wang and Tom Topping. Food, drug and medical device regulatory matters were handled by Torrey Cope, Trevor Wear, Meenakshi Datta, Elizabeth Kolbe and Zimu Yang. Katie Klaben and Louis Prieto advised on Section 16 reporting obligations. Suresh Advani and Edwin Choy handled tax matters.
*Source: Renaissance Capital/Time Periods 01/01/2016 to 07/10/2018